Literature DB >> 24216602

Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients.

Pinar Tarkun1, Elif Birtas Atesoglu, Ozgur Mehtap, Mahmut Mert Musul, Abdullah Hacihanefioglu.   

Abstract

BACKGROUND/AIMS: Multiple myeloma (MM) is a hematological cancer associated with increased clonal malignant plasma cells. Growth differentiation factor 15 (GDF 15) is a protein that is highly expressed in the bone marrow mesenchymal stem cells of patients with MM. This study investigated whether the clinical stage of the disease, treatment response and survival are affected by pretreatment serum GDF 15 levels.
METHODS: Serum GDF 15 levels were measured in 35 newly diagnosed MM patients and 27 healthy controls. The correlation between serum GDF 15 levels and various clinical and laboratory parameters was analyzed.
RESULTS: The study demonstrated significantly higher levels of GDF 15 in MM patients. There was a negative correlation between GDF 15 levels, hemoglobin and albumin levels, and a positive correlation between GDF 15 levels, CRP, creatinine, β-2-microglobulin and stage. GDF 15 levels were lower in patients who could receive autologous stem cell transplantation compared to other groups, representing a statistically significant difference. However, in the survival analyses, GDF 15 level did not have an impact on survival.
CONCLUSION: High serum levels of GDF 15 may indicate a poor treatment response. Our study supports the prognostic value of GDF 15 in MM.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24216602     DOI: 10.1159/000354835

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  6 in total

1.  Hepcidin and GDF15 in anemia of multiple myeloma.

Authors:  Shuchong Mei; Huaquan Wang; Rong Fu; Wen Qu; Limin Xing; Guojin Wang; Jia Song; Hong Liu; Lijuan Li; Xiaoming Wang; Yuhong Wu; Jin Guan; Erbao Ruan; Zonghong Shao
Journal:  Int J Hematol       Date:  2014-07-23       Impact factor: 2.490

2.  Prognostic Impact of Serum Growth Differentiation Factor 15 Level in Acute Myeloid Leukemia Patients.

Authors:  Hany Mohamed Hegab; Amro Mohamed Sedky El-Ghammaz; Mostafa Kamal El-Razzaz; Reham Ali Ali Helal
Journal:  Indian J Hematol Blood Transfus       Date:  2020-06-30       Impact factor: 0.900

3.  The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis.

Authors:  Tatsuki Uchiyama; Hiroshi Kawabata; Yasuo Miura; Satoshi Yoshioka; Masaki Iwasa; Hisayuki Yao; Soichiro Sakamoto; Masakazu Fujimoto; Hironori Haga; Norimitsu Kadowaki; Taira Maekawa; Akifumi Takaori-Kondo
Journal:  Cancer Med       Date:  2015-08-15       Impact factor: 4.452

Review 4.  New Biomarkers of Ferric Management in Multiple Myeloma and Kidney Disease-Associated Anemia.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; David H Vesole; Karolina Woziwodzka; Artur Jurczyszyn; Marcin Żórawski; Marcin Krzanowski; Jacek Małyszko; Krzysztof Batko; Marek Kuźniewski; Katarzyna Krzanowska
Journal:  J Clin Med       Date:  2019-11-01       Impact factor: 4.241

5.  Serum Growth Differentiation Factor-15/Albumin Ratio as a 2-Year Survival Marker of End-Stage Renal Disease Patients Initiating Maintenance Hemodialysis.

Authors:  Eu-Jin Lee; Haet-Bit Hwang; Soo-Hyun Han; Young-Rok Ham; Jin-Ah Shin; Kang-Wook Lee; Ki-Ryang Na; Dae-Eun Choi
Journal:  Diagnostics (Basel)       Date:  2022-01-20

6.  Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma.

Authors:  Petra Schneiderova; Tomas Pika; Petr Gajdos; Regina Fillerova; Pavel Kromer; Milos Kudelka; Jiri Minarik; Tomas Papajik; Vlastimil Scudla; Eva Kriegova
Journal:  Oncotarget       Date:  2016-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.